S C Meuer
Overview
Explore the profile of S C Meuer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
2652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sido B, Braunstein J, Breitkreutz R, Herfarth C, Meuer S
J Exp Med
. 2000 Sep;
192(6):907-12.
PMID: 10993921
Intestinal lamina propria T lymphocytes (LP-Ts) have a markedly low proliferative potential both in vivo and in vitro. Here, we have identified that the capacity of antigen-presenting cells to release...
12.
Lee K, Meuer S, Samstag Y
Eur J Immunol
. 2000 Mar;
30(3):892-9.
PMID: 10741406
The actin cytoskeletal network plays a regulatory role in receptor-mediated signal-transducing events. Recently, we have shown that the small actin-depolymerizing protein cofilin represents a component of a co-stimulatory signaling pathway...
13.
Stallmach A, Wittig B, Giese T, Pfister K, Hoffmann J, Bulfone-Paus S, et al.
Gastroenterology
. 1999 Sep;
117(4):866-76.
PMID: 10500069
Background & Aims: We have shown in previous studies that an interleukin 2 (IL-2)-IgG2b fusion protein suppresses both humoral and cellular immune reactions in a murine model of DTH reaction....
14.
Wild M, Strittmatter W, Matzku S, Schraven B, Meuer S
J Immunol
. 1999 Aug;
163(4):2064-72.
PMID: 10438945
For tumor therapy with unprimed effector cells, we developed a novel combination of a CD2 x tumor Ag bispecific targeting Ab and an anti-CD2 triggering Ab. These Ab constructs were...
15.
Meyer G, Batrla R, Rudy W, Meuer S, Wallwiener D, Guckel B, et al.
Cancer Gene Ther
. 1999 Jun;
6(3):282-8.
PMID: 10359214
Allogeneic human histocompatibility leukocyte antigen (HLA)-matched tumor cell lines that have been made immunogenic by the transfer of genes encoding for costimulatory molecules such as CD80 are considered to be...
16.
Guckel B, Meyer G, Rudy W, Batrla R, Meuer S, Bastert G, et al.
Cancer Gene Ther
. 1999 Jun;
6(3):228-37.
PMID: 10359208
One possible reason for the poor immunogenicity of tumors is the induction of peripheral tolerance by tumor cells that fail to deliver costimulatory signals. Furthermore, T cells stimulated with wild-type...
17.
Dengler T, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl C, et al.
Transplantation
. 1999 Feb;
67(3):392-8.
PMID: 10030284
Background: Allograft rejection depends on T cell immune responses requiring antigen recognition and costimulatory signals through accessory T cell receptors, including CD28. Inhibition of CD28 signaling with a CTLA-4-immunoglobulin (Ig)...
18.
Meyer G, Moebius U, Rudy W, Batrla R, Meuer S, Wallwiener D, et al.
Adv Exp Med Biol
. 1999 Feb;
451:195-202.
PMID: 10026872
No abstract available.
19.
Nebl G, Meuer S, Samstag Y
J Immunol
. 1998 Aug;
161(4):1803-10.
PMID: 9712047
Expression of the IL-2 gene requires activation of T cells through stimulation of the TCR and costimulation through accessory receptors. We have found recently that okadaic acid-sensitive Ser/Thr phosphatases are...
20.
Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir Z, et al.
Am J Pathol
. 1998 Jul;
153(1):121-30.
PMID: 9665472
A dysregulated secretion of contra-inflammatory cytokines such as interleukin-10 (IL-10) could play a role in the pathogenesis of inflammatory bowel disease (IBD). We have investigated the expression of IL-10 in...